Q-omics provides the consensus-scored RET profile across patient tissues and cancer cell-line models. RET expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RET is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RET RNA expression shows 16,152 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRC, and TGCT as cancer lineages where RET shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RET — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RET survival associations across molecular data types. RET RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RET RNA expression–survival associations across cancer types. High RET expression shows unfavorable associations in UCEC, KIRC, ACC, HNSC and STAD, but favorable associations in THCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for RET RNA expression.
This table summarizes RET tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RET. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RET shows lower tumor expression in KIRC, LIHC, KIRP and COAD and higher tumor expression in HNSC and BRCA. The KIRC box plot shows higher RET RNA expression in normal versus tumor tissue (log2 FC = −0.808, t-test p < 0.001).
This table shows molecular features associated with RET in patient tissues and cancer cell lines. In patient samples, RET shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RET RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
